Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Gains from Sales and Divestitures (2018 - 2025)

Theravance Biopharma (TBPH) has disclosed Gains from Sales and Divestitures for 7 consecutive years, with $1.8 million as the latest value for Q4 2025.

  • Quarterly Gains from Sales and Divestitures rose 11.8% to $1.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.8 million through Dec 2025, up 11.8% year-over-year, with the annual reading at $1.8 million for FY2025, 11.8% up from the prior year.
  • Gains from Sales and Divestitures for Q4 2025 was $1.8 million at Theravance Biopharma, up from $336744.0 in the prior quarter.
  • The five-year high for Gains from Sales and Divestitures was $3.8 million in Q4 2022, with the low at $297284.0 in Q3 2024.
  • Average Gains from Sales and Divestitures over 5 years is $1.3 million, with a median of $656431.0 recorded in 2024.
  • The sharpest move saw Gains from Sales and Divestitures surged 40.63% in 2021, then crashed 56.17% in 2023.
  • Over 5 years, Gains from Sales and Divestitures stood at $2.7 million in 2021, then surged by 40.44% to $3.8 million in 2022, then plummeted by 56.17% to $1.7 million in 2023, then fell by 0.64% to $1.6 million in 2024, then increased by 11.8% to $1.8 million in 2025.
  • According to Business Quant data, Gains from Sales and Divestitures over the past three periods came in at $1.8 million, $336744.0, and $413240.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.